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A b s t r A c t
bAcKGrOUND: Prolonged duration of manual or mechanical compression at the site 
of femoral artery access after sheath removal upon completion of coronary proce-
dures followed by extended period of bed rest has significant logistical and practical 
problems for both patients and hospital staff. The availability of vascular closure de-
vices (VCDs) has ushered in a new era in the routine clinical practice in the catheteri-
zation laboratory.
AIM: The aim of this prospective study was to assess the effectiveness and safety of the 
use of the VCD VasoSeal, a collagen plug, in patients undergoing cardiac catheteriza-
tion and/or percutaneous coronary intervention (PCI).
PAtIENts AND MEtHODs: VasoSeal was employed over 2.5 years in 388 consecutive 
patients mostly presenting with acute coronary syndromes and subjected mainly to 
PCI procedures performed via transfemoral arterial access. All the patients who un-
derwent PCI were given 7,000 IU of heparin intravenously during the procedure and 
had been receiving or were acutely loaded with dual antiplatelet therapy (aspirin and 
clopidogrel). The majority (90.7%) of patients also received a platelet glycoprotein 
IIb/IIIa inhibitor during and for 12-14 hours after the procedure. The sheaths were 
removed at the end of the procedure and hemostasis achieved with VasoSeal.
rEsULts: Deployment of the VCD was successful in 99.2%. Complete hemostasis 
without bleeding or hematoma was obtained in 95.4% of cases (370/388). In 3 patients 
VasoSeal could not be or was partially deployed. The mean time required for the 
placement of VasoSeal was 1 min. The mean time-to-hemostasis was 3 min. The mean 
time-to-mobilization was 3 hours. Only one patient developed a pseudoaneurysm of 
the right common femoral artery; the lesion was treated with ultrasonography -guided 
compression. In addition, 16 small local hematomas and 2 large inguinal hematomas 
(one requiring blood transfusion) were recorded. In 2 cases retroperitoneal bleeding 
occurred, requiring blood transfusion in one of them. Local infection (cellulitis) re-
sponding to antibiotic treatment was observed in 2 patients. No patient required local 
surgical intervention.
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I N t r O D U c t I O N
Vascular closure devices (VCDs) play an increasingly 
important role in the catheterization laboratory during per-
cutaneous coronary interventional (PCI) procedures as an 
alternative to manual or mechanical compression.1,2 Their 
use aims at combined expedience, safety, patient convenience 
and early mobilization, and reduced hospital resources and 
costs. Initial experience in our laboratory with such a device 
involved use of the extravascular VCD, VasoSeal (Datascope 
Corporation, Mahwah, NJ, USA) for femoral artery puncture 
site closure and hemostasis. VasoSeal is an extravascular VCD 
that achieves hemostasis via collagen-mediated thrombotic 
closure at the puncture site.3 No material is left within the 
artery and delivery is quite expedient. It accommodates various 
vessel sizes, and the presence of existing peripheral vascular 
disease does not preclude its use. Fluoroscopy is not required 
to confirm or guide access site location. Several studies have 
documented both its effectiveness and safety,3-7 albeit some 
have suggested a relatively higher risk of local complications 
in the setting of PCI.1,8-11
P A t I E N t s  A N D  M E t H O D s
Over 2.5 years, 388 consecutive patients, mostly with an 
acute coronary syndrome (ACS), were submitted to cardiac 
catheterization via a transfemoral approach by a single opera-
tor in order to perform coronary angiography and PCI. This 
was the group that was catheterized during the period when a 
vascular closure device became available in our catheterization 
laboratory to use for obtaining local hemostasis. Patients were 
excluded when transfemoral access was deemed problematic 
or impossible due to peripheral vascular disease, requiring a 
radial or brachial approach. The study was ended when a newer 
VCD became available and local hemostasis was continued 
with use of the new device. Procedures were performed 12 
years ago at two institutions with (n=25) or without (n = 363) 
cardiac surgery backup. Vascular surgery back-up was available 
at both institutions. An informed written consent was obtained 
from each patient before the procedure.
Arterial access was routinely obtained via the right femo-
ral artery and occasionally via the left femoral artery in cases 
where vascular access problem was anticipated or encoun-
tered from the right femoral artery or when repeat access 
was required at a short period after a right inguinal puncture. 
Selection of the entry site was guided by a combination of 
anatomical landmarks. Usually, the artery was entered 2 to 
3 cm below the midpoint of the inguinal skin crease or at the 
midpoint between the anterior superior iliac spine and pubic 
tubercle, guided by palpation of the maximal arterial pulse. 
A modified Seldinger technique was used for arterial access 
and sheath insertion. 
A 6 French femoral sheath was routinely used except when a 
demanding PCI procedure was planned, in which case a 7 French 
sheath was employed. After arterial access was secured, 2,500 
U of intravenous unfractionated heparin was given. when after 
completion of coronary angiography a decision was made to 
proceed with adhoc PCI, an additional 7,000 U of heparin were 
administered. when feasible, activated clotting time (ACT) was 
monitored during the PCI procedure and maintained at ≥300 
sec with adjusted heparin doses or additional 2,000 U of heparin 
were administered every 1 hour during prolonged procedures. 
All patients had received dual antiplatelet therapy with aspirin 
and clopidogrel prior to catheterization usually with a loading 
dose (500 mg and 300 mg, respectively) provided upon admission 
for those with ACS. As the majority of patients presented with 
ACS, they also received a glycoprotein IIb/IIIa inhibitor during 
the PCI procedure. All three IIb/IIIa agents were available for 
use. Abciximab was given at a loading dose of 0.25 mg/kg IV 
followed by maintenance dose of 0.125 mcg/kg/min IV infusion 
for 12 hours; eptifibatide was given at one loading dose of 180 
mcg/kg, followed by maintenance dosing at 2 mcg/kg/min for 24 
hours; tirofiban infusion was given at an initial dose of 0.4 mcg/
kg/min for 30 minutes, then reduced to 0.1 mcg/kg/min which 
was continued for 24 hours. 
when the procedure was completed, reversal of the effect 
of heparin was not performed. For manual compression, the 
sheath was removed when the ACT was <200 sec. However, 
when the vascular closure device was used, the sheath was 
removed immediately without checking the ACT.
VA s c U L A r  c L O s U r E  D E V I c E
The VasoSeal (Datascope Corporation, Mahwah, NJ, 
USA) vascular closure device is totally extravascular, delivering 
purified bovine collagen into the tissue tract created by the re-
moval of the femoral sheath (Figure 1). It achieves hemostasis 
via collagen-mediated thrombotic closure at the puncture site. 
Fluoroscopy is not required to guide its deployment. A sterile 
dressing is applied afterwards at the entry site and pressure is 
applied for ~5 minutes. 
cONcLUsION: VasoSeal was a safe collagen closure device characterized by a high success rate of deployment and highly suc-
cessful hemostasis with few manageable complications in a very high-risk patient cohort undergoing PCI under heavy anticoagu-
lation and antiplatelet drug therapy. In these patients this vascular closure device reduced the time-to-hemostasis and time-to-
mobilization and the incidence of complications.
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years (range 33-87 years) (Table 1). Diabetes mellitus was 
present in 92 (24%) patients. The majority (n=354, 91.2%) 
were patients admitted with an ACS. A total of 381 (98.2%) 
patients underwent a PCI procedure, which was performed 
adhoc (during the same session as coronary angiography) in 
267 (70%) patients. PCI was performed on a mean number 
vessels of 1.22±0.45 with a mean of 1.8±0.96 lesions dilated 
and/or stented. Stents were used in 356 (93%) patients; bare 
metal stents in 195 (54%) patients, endothelial progenitor cell 
capture stents in 145 (41%) patients; and drug-eluting stents 
in 16 (5%) patients. The mean left ventricular ejection frac-
tion was 52.5±8.9% (range, 20-80%). A platelet glycoprotein 
IIb/IIIa inhibitor was administered in 352 (90.7%) patients. 
The right femoral artery was accessed in 382 patients and 
the left femoral artery in 6 patients. Successful VCD deploy-
ment was achieved in 385 (99.2%) patients. In one patient 
insertion of the device failed completely, while in the other 
two there was incomplete deployment and in all three cases, 
manual compression was applied. 
The mean time required for the placement of VasoSeal 
was 1 min. The mean time-to-hemostasis was 3 min. The mean 
time-to-mobilization was 3 hours.
tAbLE 1. Characteristics of Patients Receiving the Vascular 
Closure Device (VasoSeal)
Patients 388
Female 63
Age (years) 59.8±10.8 
Acute coronary syndrome 354 (91.2%)
Left ventricular ejection fraction (%) 52.5±8.9
Access
RFA 382
LFA 6
Procedure
PCI 381
CATH 7
Adhoc PCI 267 (70%)
PCI
Number of vessels 1.22±0.45
Number of lesions 1.80±0.96
Stent procedures 356 (93.4%)
Diabetics 92 (24%)
IIb/IIIa agents 352 (91%)
CATH = (cardiac) catheterization (coronary angiography); LFA = 
left femoral artery; PCI = percutaneous coronary intervention; RFA 
= right femoral artery
FIGUrE 1. VasoSeal was an extravascular collagen plug deliv-
ered to the entry site. First the dilator and the sheath ensemble 
were advanced over the guidewire to prior demarcated depth at 
the outer border of the femoral artery at the entry site; then the 
dilator was removed and the collagen plug was injected through 
the sheath into the skin tract while simultaneously withdraw-
ing the delivery apparatus thus sealing the arteriotomy site with 
resultant hemostasis. The device was suitable for use with 5-8 
French sheath sizes.
An attempt was made to record the time to hemostasis and 
to ambulation after the deployment of the VCD. Complica-
tions were recorded in every patient when it occurred. All 
data were collected prospectively. All patients were followed 
closely until discharge. 
The occurrence of a pseudoaneurysm, arterio-venous fis-
tula, arterial thrombosis, need for vascular surgery, retroperi-
toneal bleed, local abscess, bleeding or large hematoma at the 
puncture site requiring transfusion, or in-hospital death were 
considered as major complications. Routine duplex ultrasound 
was not performed to check the puncture site unless there was 
a clinical suspicion of a pseudoaneurysm or a fistula. A minor 
complication was defined as a localized allergic reaction or 
cellulitis or a hematoma not requiring transfusion. Failure to 
deliver the collagen to the puncture site was recorded as VCD 
deployment failure.
s t A t I s t I c s
Data are presented as descriptive statistics with use of 
mean ± standard deviation and/or percentages. 
r E s U L t s
A total of 388 consecutive patients (63 women) receiving a 
VCD were included in the study, with a mean age of 59.8±10.8 
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c O M P L I c A t I O N s
No patient had an arterio-venous fistula. One patient 
developed a pseudoaneurysm of the right common femoral 
artery; the lesion was treated with ultrasonography -guided 
compression. In addition, 16 small local hematomas and 1 large 
inguinal hematomas were recorded (Table 2). One additional 
large hematoma occurred which required blood transfusion. 
In 2 cases retroperitoneal bleeding occurred, requiring blood 
transfusion in one of them. Local infection (cellulitis) respond-
ing to antibiotic treatment was observed in 2 patients. No cases 
of arterial thrombosis occurred and no patient required local 
surgical intervention. 
to achieve hemostasis and earlier patient ambulation, and to 
greater cost-effectiveness.15 However, complications at the site 
of femoral artery access still occur.8,10 
Manual compression can take 20-30 minutes or even more 
to accomplish hemostasis.2 However oftentimes, especially if a 
patient has been administered antithrombotic and anticoagu-
lant drugs prior to the percutaneous procedure, sheath removal 
is deferred for later, occasionally for several hours,15 for the 
anticoagulant effect to dissipate (e.g. until the measured ACT 
drops below 180-200 sec) and reduce the risk of bleeding before 
manual compression can be successfully applied on the punc-
ture site. Reversal of the coagulant effect may be used when 
the procedure is limited to diagnostic coronary angiography, 
albeit many operators may skip the use of heparin in diagnostic 
procedures, but when PCI is performed, whereby heavy an-
ticoagulation is routinely employed, reversal is avoided due 
to risk of coronary vessel occlusion and/or stent thrombosis. 
Several trials have evaluated efficacy and safety of 
VCDs,1,2,4,8,11,16  but there is still a paucity of strong data from 
randomized clinical trials establishing the superiority of VCDs 
over manual or mechanical compression.17 In diagnostic proce-
dures where no or minimal anticoagulation is used, VCDs are 
effective and more practical over manual compression. How-
ever, when heavy anticoagulation and/or antiplatelet therapy 
is employed, like during PCI procedures, safety is sought in 
addition to efficacy, since these demanding procedures are as-
sociated with lower success and higher complication rates for 
both methods of hemostasis (manual compression or VCDs). 
Among the drawbacks of VCDs, deployment failure is 
a major issue,18 but more important are the local complica-
tions that may ensue, which may lead to leg ischemia and/or 
need for vascular surgery with its attendant risks. Data from 
various meta-analyses have demonstrated that complications 
and success rates may not be significantly different between 
mechanical compression and VCDs.8,9,11 It appears that this 
may finally be operator dependent despite that the learning 
curve appears to be relatively short. Integration of clinical data, 
having performed the arterial puncture at the correct site and 
familiarizing oneself with a particular VCD seem to play a key 
role in successfully deploying the device and achieving com-
plete hemostasis and avoiding disastrous local complications. 
Deployment of older generation VCDs was cumbersome and 
benefits were not that apparent compared with manual com-
pression, particularly with regards to safety.11,16,18,19 However, 
newer generation devices have overcome such limitations and 
have contributed to reduced local complication rate.17
In the present study, we have demonstrated a high (99%) 
success rate of initial deployment of the VCD with also a high 
(95%) rate of successful final hemostasis in a large cohort of 
high-risk patients with acute coronary syndromes undergoing 
PCI procedures via a transfemoral approach. A heavy use of 
anticoagulation and/or strong antiplatelet therapy with IIb/IIIa 
inhibitors on top of dual antiplatelet therapy did not lead, as 
tAbLE 2. Procedural Characteristics of 388 Patients Re-
ceiving VasoSeal
Successful deployment 385 (99.2%)
Failed deployment 3
Complications 23 (5.9%)
Groin hematomas 16
Large groin hematomas   2*
Retroperitoneal bleeding   2*
Cellulitis 2
Pseudoaneurysm     1**
Arteriovenous fistula 0
Local vascular surgery 0
*1 patient required blood transfusion; **managed with Doppler-guided 
local compression
D I s c U s s I O N
Historically, femoral arterial access for cardiac catheteriza-
tion procedures has necessitated prolonged (≥20-30 minutes) 
manual compression and extended (≥6-12 hours) bed rest 
following sheath removal.2,12,13 Over the last almost 20 years, 
vascular closure devices (VCDs) have become available to 
improve upon achieving quicker hemostasis, but it is mostly 
with the availability of newer generation products over the 
last decade that VCDs have become more widely utilized in 
clinical practice to allow for early ambulation and to shorten 
patients’ hospital stay.1,2 In the setting of percutaneous coro-
nary intervention (PCI), VCDs have emerged as a practical 
alternative to manual or mechanical compression in an attempt 
to achieve faster hemostasis at the puncture site of the femoral 
artery and earlier patient mobilization. VCDs are categorized 
mainly based on the mechanism of hemostasis they provide, 
which includes biodegradable collagen or other plug, staples, 
or sutures.14 VCDs do offer advantages over mechanical com-
pression which relate to patient convenience from shorter time 
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it might have been expected, to inordinate local complication 
rate. In contrast, only 2 patients sustained major bleeding 
(inguinal or retroperitoneal) requiring blood transfusion, and 
only one additional patient developed a local pseudoaneurysm 
treated conservatively with ultrasound-guided compression. It 
is important to note that our study results regarding success 
and complication rates are consistent with other previously 
published data concerning patients who underwent vascular 
radiological intervention procedures.5
s t U D y  L I M I t A t I O N s
Although this is a prospective study, it lacks randomization 
with a control group of patients having manual compression 
during the same time period. This is because the VCD was 
employed systematically in all consecutive patients undergo-
ing cardiac catheterization during the study period, except 
for patients having peripheral vascular disease who had the 
procedure done via a radial or brachial approach, and thus 
there was no group having concurrent manual compression 
to compare with. The lack of 30-day follow-up in this cohort 
may be considered another limitation of the present study, 
but it has been demonstrated by other studies that most of the 
events (95.5%) occur during hospitalization.17 
c O N c L U s I O N
VasoSeal was a safe collagen vascular closure device 
characterized by a high (99%) success rate of deployment and 
highly successful hemostasis with few manageable (1% major 
and 4.9% minor) complications in a very high-risk patient 
cohort undergoing PCI under anticoagulation and antiplatelet 
therapy. In these patients this vascular closure device reduced 
the time-to-hemostasis and time-to-mobilization and the inci-
dence of complications. Newer generation devices, to which 
we have switched to at the end of the present study, appear 
more promising in terms of efficacy and safety,17 and even 
cost-effectiveness,15 while increasing adoption of the radial 
approach as an alternative access for cardiac catheterization 
may further reduce access site complications.20
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